Zenobia Therapeutics Begins Operations as a Fragment Based Lead Discovery Company
News Jul 24, 2008
Zenobia Therapeutics, Inc. announced that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and moved into their new laboratory and office facilities on July 1. The Zenobia team is said to be leaders in the areas of high-throughput structural biology and fragment-based lead discovery (FBLD).
Zenobia will focus on limited population diseases that are traditionally not pursued by larger companies. Zenobia combines the early-stage drug discovery method of FBLD with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy.
"There is a niche for companies that are passionate about applying innovative approaches to diseases that are not being addressed by mainstream drug discovery organizations," says Dr. Vicki Nienaber, President and founder of Zenobia.
"Our mission is to find cures for these patients by working with foundations, granting agencies and leading biologists and clinicians." Zenobia will also provide access to their technology through a limited number of collaborations and partnerships.
Zenobia's 505 Coast Blvd facility is fully equipped for cloning, expression, purification and crystallization of proteins. Contracts are in place with synchrotron facilities for high-throughput data collection and Zenobia's compound library is available for screening. Drug discovery chemistry and pharmacology will be accessed through contract research organizations and consultants.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.